Zacks Research Issues Pessimistic Outlook for COO Earnings

The Cooper Companies, Inc. (NASDAQ:COO) – Analysts at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of Cooper Companies in a research report issued on Thursday, March 27th. Zacks Research analyst I. Bandyopadhyay now expects that the medical device company will earn $0.93 per share for the quarter, down from their previous forecast of $0.94. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.20 EPS, Q1 2027 earnings at $1.10 EPS and FY2027 earnings at $4.85 EPS.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The company had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%.

Several other research analysts have also recently issued reports on the stock. Robert W. Baird lowered their target price on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a report on Friday, March 7th. BNP Paribas raised shares of Cooper Companies to a “hold” rating in a report on Thursday, March 13th. Wells Fargo & Company increased their price target on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, December 6th. Morgan Stanley cut their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Friday, December 6th. Finally, JPMorgan Chase & Co. reduced their price target on Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.25.

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $84.35 on Monday. The stock’s 50-day simple moving average is $89.15 and its 200-day simple moving average is $97.03. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The firm has a market capitalization of $16.87 billion, a PE ratio of 43.26, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. Cooper Companies has a fifty-two week low of $77.05 and a fifty-two week high of $112.38.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in COO. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Cooper Companies during the fourth quarter valued at about $691,000. Highland Capital Management LLC bought a new stake in Cooper Companies during the 4th quarter valued at approximately $4,004,000. Caprock Group LLC bought a new stake in Cooper Companies during the 4th quarter valued at approximately $282,000. Franklin Resources Inc. lifted its holdings in shares of Cooper Companies by 194.0% during the third quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock worth $5,265,000 after buying an additional 32,260 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in Cooper Companies by 6.6% during the 3rd quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock valued at $26,295,000 after purchasing an additional 14,687 shares during the last quarter. 24.39% of the stock is owned by institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.